Literature DB >> 12748009

MRI-guided stereotactic biopsy in the diagnosis of glioma: comparison of biopsy and surgical resection specimen.

Matthew J McGirt1, Alan T Villavicencio, Ketan R Bulsara, Allan H Friedman.   

Abstract

BACKGROUND: Although there has been a dramatic increase in the accessibility and utilization of high-resolution MRI techniques for the evaluation of brain tumors, there is currently only a single report comparing stereotactic brain biopsy specimen to subsequent resection specimen exclusively in the management of gliomas.
METHODS: The diagnoses in 43 cases of astrocytic brain tumors were derived using MRI-guided stereotactic biopsy followed by open resection of the lesion. The histologic diagnoses yielded by biopsy were compared with subsequent histologic diagnosis after open tumor resection. All biopsies and histologic diagnoses were made by the same surgeon and pathologist, respectively.
RESULTS: In 23 patients undergoing resection <60 days after biopsy, the biopsy diagnosis was consistent with resection diagnosis in 18 cases (79%) and led to the correct treatment in 22 cases (96%). Recurrent glioblastoma multiforme (GBM) was undergraded as anaplastic astrocytoma in 4 patients. GBM was misdiagnosed as radiation necrosis in 1 patient. MR-nonenhancing lesions [10/10 (100%)] yielded histology that correlated with subsequent craniotomy, while only 8/13 (61%) MR-enhancing lesions yielded histology that was consistent with that at craniotomy (p < 0.05). In 20 patients undergoing resection because of radiologic tumor progression (mean 7 months after biopsy), 6/6 (100%) biopsy diagnoses of a specific glioma grade correlated with resection diagnosis, while only 6/14 (43%) biopsy diagnoses of radiation effect correlated with resection diagnosis (p < 0.01).
CONCLUSION: MRI-guided stereotactic brain biopsy specimen accurately represents the grade of the larger glioma mass sufficiently to guide subsequent therapy. Enhancement on MR may be a negative prognostic indicator of biopsy accuracy.

Entities:  

Mesh:

Year:  2003        PMID: 12748009     DOI: 10.1016/s0090-3019(03)00048-x

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  18 in total

1.  Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas.

Authors:  Michail Plotkin; C Blechschmidt; G Auf; F Nyuyki; L Geworski; T Denecke; W Brenner; F Stockhammer
Journal:  Eur Radiol       Date:  2010-06-03       Impact factor: 5.315

Review 2.  Glioblastoma: Part I. Current state of affairs.

Authors:  Michael E Salacz; Kenneth R Watson; David A Schomas
Journal:  Mo Med       Date:  2011 May-Jun

3.  Predictors and early survival outcomes of maximal resection in WHO grade II 1p/19q-codeleted oligodendrogliomas.

Authors:  Maya Harary; Vasileios K Kavouridis; Matthew Torre; Hasan A Zaidi; Ugonma N Chukwueke; David A Reardon; Timothy R Smith; J Bryan Iorgulescu
Journal:  Neuro Oncol       Date:  2020-03-05       Impact factor: 12.300

4.  Brainstem glioma: Prediction of histopathologic grade based on conventional MR imaging.

Authors:  Yashar Moharamzad; Morteza Sanei Taheri; Farhad Niaghi; Elham Shobeiri
Journal:  Neuroradiol J       Date:  2017-11-17

5.  Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.

Authors:  Laia Capdevila; Sara Cros; Jose-Luis Ramirez; Carolina Sanz; Cristina Carrato; Margarita Romeo; Olatz Etxaniz; Cristina Hostalot; Ana Massuet; Jose Luis Cuadra; Salvador Villà; Carmen Balañà
Journal:  J Neurooncol       Date:  2014-01-07       Impact factor: 4.130

6.  Preoperative relative cerebral blood volume analysis in gliomas predicts survival and mitigates risk of biopsy sampling error.

Authors:  Brendan J McCullough; Valerie Ader; Brian Aguedan; Xu Feng; Daniel Susanto; Tara L Benkers; John W Henson; Marc Mayberg; Charles S Cobbs; Ryder P Gwinn; Stephen J Monteith; David W Newell; Johnny Delashaw; Sarah J Fouke; Steven Rostad; Bart P Keogh
Journal:  J Neurooncol       Date:  2017-11-02       Impact factor: 4.130

7.  Is biopsy needed to guide management for all patients with presumed intracranial ectopic germinomas.

Authors:  Chenglin Tian; Chuanqiang Pu; WeiPing Wu; Xusheng Huang; Senyang Lang; Shengyuan Yu; Jiatang Zhang; Dehui Huang; Shuxiang Cui
Journal:  J Neurooncol       Date:  2008-10-26       Impact factor: 4.130

8.  Diagnostic challenges of primary thalamic gliomas-identification of a minimally enhancing neuroradiological subtype with aggressive neuropathology and poor clinical outcome.

Authors:  K M Kurian; Y Zhang; H R Haynes; N A Macaskill; M Bradley
Journal:  Clin Neuroradiol       Date:  2013-05-25       Impact factor: 3.649

9.  Low-grade gliomas in older patients: a retrospective analysis of prognostic factors.

Authors:  Nader Pouratian; Melike Mut; Jay Jagannathan; M Beatriz Lopes; Mark E Shaffrey; David Schiff
Journal:  J Neurooncol       Date:  2008-08-06       Impact factor: 4.130

10.  Diffusion Histology Imaging Combining Diffusion Basis Spectrum Imaging (DBSI) and Machine Learning Improves Detection and Classification of Glioblastoma Pathology.

Authors:  Zezhong Ye; Richard L Price; Xiran Liu; Joshua Lin; Qingsong Yang; Peng Sun; Anthony T Wu; Liang Wang; Rowland H Han; Chunyu Song; Ruimeng Yang; Sam E Gary; Diane D Mao; Michael Wallendorf; Jian L Campian; Jr-Shin Li; Sonika Dahiya; Albert H Kim; Sheng-Kwei Song
Journal:  Clin Cancer Res       Date:  2020-07-21       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.